Exelixis (EXEL) Net Cash Flow Growth (5y) (2015 - 2026)
Exelixis (EXEL) Net Cash Flow Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,094.26 Bn | 68,093.97 Bn | - |
| 2 | Nanobiotix | 1,939.09 Bn | 1,939.02 Bn | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - |
| 4 | BeOne Medicines | 473.53 Bn | 468.74 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.34 Bn | 116.09 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.13 Bn | 61.38 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.96 Bn | 62.96 Bn | - |
| 8 | Argenx Se | 56.38 Bn | 51.20 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn |
| 10 | Exelixis | 14.59 Bn | 13.81 Bn | 590.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | -35.60% |
| Jan 2, 2026 | -3.24% |
| Apr 4, 2025 | -18.84% |
| Sep 27, 2024 | 19.82% |
| Jun 28, 2024 | -71.26% |
| Mar 29, 2024 | -15.53% |
| Dec 29, 2023 | -27.74% |
| Sep 29, 2023 | -21.45% |
| Jun 30, 2023 | -47.37% |
| Mar 31, 2023 | -3.06% |
| Dec 30, 2022 | -47.89% |
| Sep 30, 2022 | 22.54% |
| Jul 1, 2022 | -15.98% |
| Apr 1, 2022 | 18.43% |
| Dec 31, 2021 | 26.33% |
| Oct 1, 2021 | 38.96% |
| Jul 2, 2021 | 22.97% |
| Apr 2, 2021 | -6.02% |
| Apr 3, 2020 | 81.66% |
| Sep 27, 2019 | -21.96% |